Literature DB >> 15905557

Adoptive transfer of in vitro-stimulated CD4+CD25+ regulatory T cells increases bacterial clearance and improves survival in polymicrobial sepsis.

Josef G Heuer1, Tonghai Zhang, Jingyong Zhao, Chunjin Ding, Martin Cramer, Kathy L Justen, Steven L Vonderfecht, Songqing Na.   

Abstract

Regulatory CD4(+)CD25(+) T cells (Tregs) suppress autoimmune and inflammatory diseases through mechanisms that are only partly understood. Previous studies suggest that Tregs can suppress bacterially triggered intestinal inflammation and respond to LPS through TLRs with enhanced suppressive activity. In this study, we have used murine cecal ligation and puncture as a model of polymicrobial sepsis to explore the effects of adoptive transfer of Tregs on septic outcome. Adoptive transfer of in vitro-stimulated Tregs in both prevention and therapeutic modes significantly improved survival of cecal ligation and puncture mice. Furthermore, the effect was dependent on both the number of Tregs adoptively transferred and the presence of host T cells. Animals that received stimulated Tregs had significantly increased peritoneal mast cells and peritoneal TNF-alpha production. More importantly, adoptive transfer of in vitro-stimulated Tregs significantly improved bacterial clearance, which resulted in improved survival. Our results suggest a novel role for Tregs in sepsis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905557     DOI: 10.4049/jimmunol.174.11.7141

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

Review 1.  The role of lymphocytes in the development and treatment of alopecia areata.

Authors:  Hongwei Guo; Yabin Cheng; Jerry Shapiro; Kevin McElwee
Journal:  Expert Rev Clin Immunol       Date:  2015-09-07       Impact factor: 4.473

2.  Canadian practice guidelines for surgical intra-abdominal infections.

Authors:  Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

3.  The kinetics of T regulatory cells in shock: beyond sepsis.

Authors:  Eirini Christaki; Eleni Patrozou
Journal:  Crit Care       Date:  2010-03-19       Impact factor: 9.097

Review 4.  The role of regulatory T cells in immune dysfunction during sepsis.

Authors:  Chao Cao; Tao Ma; Yan-Fen Chai; Song-Tao Shou
Journal:  World J Emerg Med       Date:  2015

5.  Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism.

Authors:  Jacqueline Unsinger; Hirotaka Kazama; Jacqueline S McDonough; Thomas S Griffith; Richard S Hotchkiss; Thomas A Ferguson
Journal:  J Immunol       Date:  2010-05-12       Impact factor: 5.422

Review 6.  Mast cell and T cell communication; amplification and control of adaptive immunity.

Authors:  Alon Y Hershko; Juan Rivera
Journal:  Immunol Lett       Date:  2009-11-10       Impact factor: 3.685

7.  Systemic inflammatory response elicited by superantigen destabilizes T regulatory cells, rendering them ineffective during toxic shock syndrome.

Authors:  Ashenafi Y Tilahun; Vaidehi R Chowdhary; Chella S David; Govindarajan Rajagopalan
Journal:  J Immunol       Date:  2014-08-04       Impact factor: 5.422

8.  The relationship between CD4+CD25+CD127- regulatory T cells and inflammatory response and outcome during shock states.

Authors:  François Hein; Frédéric Massin; Aurélie Cravoisy-Popovic; Damien Barraud; Bruno Levy; Pierre-Edouard Bollaert; Sébastien Gibot
Journal:  Crit Care       Date:  2010-02-15       Impact factor: 9.097

9.  Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF.

Authors:  Rajesh K Sharma; Anna T Rogojina; K V Chalam
Journal:  Mol Vis       Date:  2010-10-27       Impact factor: 2.367

10.  Multiplex immunoassay analysis of biomarkers in clinically accessible quantities of human aqueous humor.

Authors:  Rajesh K Sharma; Anna T Rogojina; K V Chalam
Journal:  Mol Vis       Date:  2009-01-14       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.